πŸ‡ΊπŸ‡Έ FDA
Patent

US 11332470

CXCR4 inhibitors and uses thereof

granted A61PA61P35/00A61P43/00

Quick answer

US patent 11332470 (CXCR4 inhibitors and uses thereof) held by X4 Pharmaceuticals, Inc. expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
X4 Pharmaceuticals, Inc.
Grant date
Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P35/00, A61P43/00